I N T R O D U C T I O N
The Johns Hopkins Oncology Center (JHOC) was organized in 1976 as part of the National Cancer Program sponsored by the National Cancer Institute. It grew out of a series of separate departmental activities at Johns Hopkins and was designed to bring together a multidisciplinary, focused approach to cancer. Housed in a separate building in the Johns Hopkins Hospital complex, the center has 60 high-technology single-patient beds, an active outpatient clinic capable of seeing 500 patients per week, educational and administrative space, and 36,000 square feet of laboratory research space.
The goals of the Oncology Center are (1) basic and clinical research; (2) education of postgraduate fellows, house staff, medical students, community physicians, nurses, physician's assistants, radiation therapy technicians, and others; and (3) specialized clinical management of patients with cancer. To support the goals of the center, a data system has been implemented that focuses on the individual patient and the medical provider. All data items collected are oriented toward identifying patient events without regard to where the patient may be treated (inpatient, outpatient). The computing system organizes data collection and correlates data items within specific time frames. It pro-cesses multiple data items within or between groups of patients to support clinical decision making, administration, and research.
The Oncology Center Information System (OCIS) is managed by the Oncology Center administration. The OCIS supports several data activities such as the Johns Hopkins Hospital Tumor Registry and several national data exchanges, for example, the reporting requirements for ECOG (The Eastern Cooperative Oncology Group) and CCPDS (Centralized Cancer Patient Data System). There is a separate budget for data system support, and the OCIS owns and operates its own computer with full responsibility for input/output decisions and operating practices.
The primary emphasis of the system is the collection and use of clinical information for prospective application in both clinical trials and individual therapy. Special tools have been developed to assist in identifying patients on study, displaying summary onstudy data, and supporting retrospective analysis. The operation of the system is supported primarily from patient care revenue.
Information on all patients admitted to the Johns Hopkins Oncology Center inpatient or outpatient units is entered into the OCIS. Among these data are the routine demographic information, history of prior therapy, laboratory results such as hematology and chemistry data, and special-purpose data from research laboratories. In addition, quantitative measurements of the patient's status such as the performance level, pertinent symptoms, and physical findings are recorded. This information is collected at each clinic visit for outpatients and daily for patients on the inpatient services.
The data base is kept current by a data entry staff and clinical data coordinators. The former process results as they are delivered to the OCIS. Whenever possible, direct computer-to-computer transfer is used to transmit data. A data coordinator is part of the clinical unit's health care team and is responsible for the completeness and accuracy of the data base. The coordinator also assists the physician in obtaining the necessary outputs from the system. Most data products are delivered as printed output to the clinical units in time for use during morning rounds. CRT terminals are available at each nursing station and in the outpatient areas for on-line query. Data are available from the CRT within 2 hours of receipt or collection.
The OCIS operates on a dedicated minicomputer (PDP-11/70) and was developed in MUMPS. The system supports over 50 on-line terminals. The system design facilitates use by physicians and others without formal training in the use of computers. Implementation has been divided into two phases. The first concentrated upon collection and display of an accurate and timely data base. The second phase (currently being introduced) emphasizes interpretation of the data to produce protocol-directed care plans and the development of statistical analytic capabilities.
The presc:~ation to follow will expand upon the above brief description and describe the use of the system as an aid to timely and complete data collection, internal organization of information, and analysis. We will also indicate areas where the system has an impact on the control of costs of medical care and where research and the generation of new knowledge is a direct outcome of the system.
DEVELOPMENTAL HISTORY OF THE OCIS
The development of the OCIS was begun in the mid-1970s when plans were made to consolidate various oncology activities in a single facility. While there was no funding for a computer or software, the facility architecture and staffing profiles were predicated upon the assumption that a computer system would be available. Over 250 wall jacks were set into place, with cables terminating in a computer room.
During the period of planning, it was decided to begin the development of a prototype system. At this time, outpatients were being treated in a Johns Hopkins clinic, and inpatients were being treated at Baltimore city hospitals. In each case, procedures had been established for patient management based upon the careful evaluation and monitoring of clinical data. It was recognized that the labor-intensive procedures in use for that population could not be extrapolated to support a facility with 56 beds and up to 100 outpatient visits a day. Clearly, computer support was required.
On the basis of the Oncology Center's clinical practices, it was determined that an information system must (a) organize and display the clinical data as an integrated report that combined inpatient and outpatient data in ways that could indicate trends and facilitate decision making; (b) manage the basic patient record functions, including a hospitalwide tumor registry, summary patient abstracts, current census, and appointments; (c) schedule patient care activities and therapies as determined by clinical algorithms--since most cancer therapies involve sequences of actions over long periods of time, the ability of the computer to provide reminders was considered an important tool for dealing with the problem of information overload; (d) maintain clinical data for retrospective analysis. Consequently, in July 1975, 1 year before the center was to open, work on a prototype began.
The first task in the development of a prototype was the conversion of an automated tumor registry file into a format that would be expanded to support the needs of the center. The data base was transferred, and programs were developed to produce patient abstracts such as that shown in Figure 1 . At the same time, work began in the development of formats that could display clinical data effectively. Flow sheets and printer plots were designed and, after many iterations, the formats presented in the following sections were established.
The prototype system operated on a computer at the Applied Physics Laboratory. The tumor registry was a functional system with a current data base. It ran in the batch mode and was used for searches, reports, abstract generation, and quality assurance. The remainder of the prototype system was used on a limited basis. Because of the difficulty in establishing a current data base, the display system was most effective for retrospective studies; its primary contribution was the establishment of data base format requirements.
In 1976, in part as the result of a gift from the Educational Foundation of America, there were sufficient funds available to purchase a computer and support the development of a system for the Oncology Center. Called the Phase I system, this would convert the prototype to operate as an interactive system on a dedicated computer. A PDP-11 was selected with MUMPS as the development environment. Work on the prototype system stopped, and the development of the new system began. Table 1 contains a brief chronology of the system development activity. As can be seen, the prototype system was converted tO an on-line system using the prototype's data base in a period of 9 months. The reasons for this rapid implementation were (1) the existence of a prototype so that the design requirements were well known, (2) the use of MUMPS with its powerful data access tools and interactive debugging, and (3) the fact that all activity was devoted to development with no effort spent on system maintenance. Development of the system continued and new functions were added: bacteriology reports sorted by data, organism, or specimen; appointment system including scheduling of tests; pheresis system to manage blood product donation and transfusion; expansion of the administrative functions to include charge capture and level of care reporting; and the implementation of the daily care plans.
The success of the OCIS began to limit its effectiveness. The system became saturated at 20 jobs, daily production processing required 20 hours a day, it was difficult to add new functions to the existing system, and during periods of computer downtime there was no automated backup. It was therefore decided to add a second computer, which would expand functionality and provide a backup capability.
The second computer was installed in 1980. At this time Standard MUMPS was available and the previous version of MUMPS was no longer supported. Because the two versions were sufficiently different, it was decided to reprogram the OCIS rather than convert it. This became known as the Phase II system. It also was decided to use a new programming tool, TEDIUM TM, which would provide data base management system functionality and improve system maintainability. Unfortunately, TEDIUM TM was only in its initial stage of development and the development staff was faced with (1) conversion of what was by now a complex system, (2) maintenance of the old MUMPS system, and (3) the use of a new and poorly documented tool. The result was a major slip in the schedule and some user frustration. However, the conversion was successful. Parts of the new system were put into operational use in 1981, and the old MUMPS system was retired in 1982.
The two OCIS computers are now linked with distributed data base software; continuous clinical and administrative support is provided. There is a direct link to the Department of Laboratory Medicine's computer system and all test results are automatically transferred to OCIS. The OCIS computer is also used to support a hospitalwide ambulatory care system and an Oncology Center pharmacy system. Data communication between these systems and the OCIS has been implemented. Table 2 presents some survey information about the OCIS (not including the pharmacy system oJ( the administrative system). The two-computer configuration supports 60 jobs at any one time. We are now at work on the Phase III system, which will have This brief historical record has touched upon the software development process. Frequently, this is the critical link in system implementation. Nevertheless, it must be recognized that an information system involves more than computer programs. A staff must be hired and trained, users must be oriented, and the commitment to system use must be made. The installation of an HIS typically takes from 6 months to 2 years without any programming activity. In the case of the OCIS, we have been working on this problem for 7 years and have developed (and thrown away) a prototype and a Phase I system. What exists today is used and is considered an integral part of patient care and center operation. But is was neither easy nor fast, and it required the dedicated effort of a great many people to develop.
PATIENT CARE/EDUCATION
Optimal clinical management requires an organized approach to medical decisions and the availability of a complete set of facts about the patient and his disease. The computer-based data system lends itself directly to this need.
The Abstract
The patient's diagnosis must be documented and the level of reliability by which the diagnosis is known should be recorded. In addition, the sequence of any prior treatment and the response to that treatment must be known if a valid judgment as to the potential of response to the next treatment is to be made. Factors such as estrogen receptor status in breast cancer patients, histologic grade of the tumor, and the depth of penetration of a superficial cancer such as a melanoma are variables that influence decisions both at the outset and during the course of a patient's treatment.
To meet this data need, the Oncology Center has developed a format called the Abstract. The Abstract contains the minimum amount of data retained on all patients seen in the center. Every patient under the care of a physician at the center has these data summarized from the medical record and stored in the Abstract format. All Abstracts are always available on line to provide data for physicians who may be seeing the patient for the first time, to give a continuing reference for the reevaluation of treatment plans, and to support any change in treatment that may be considered. Figure 1 shows The Abstract is a statement about many important factors in the patient's care, but it is not meant to be a substitute for the complete hospital chart. However, the availability of these data in an on-line mode is an important adjunct to patient care since it provides immediately useful, focused data at any time of the day or night when the availability of the hospital chart may be limited. It also is a demonstration of the ideal minimum amount of information necessary for patient care and serves as an educational tool since the chronological organization of treatments strengthens the student's concept of the therapeutic decisions that have been made. The Abstract also often serves as the initial data base for new clinical research projects under consideration by staff or students.
Data Flows and Plots
The use of prospective clinical treatment protocols with evaluation parameters clearly defined at the outset is common in oncology clinical trials. An extension of this approach can be used to describe the management of many medical problems in which the relationship involving laboratory tests, clinical findings, and treatment must be known so that the changes brought about by treatment can be measured. This approach requires that specific physical findings, symptoms, laboratory tests, and other measures of disease and treatment must be selected at the outset, measured and recorded, and then used in a before/after model to measure the outcome of treatment and the progression or regression of the disease under treatment. The recording and display of these data is carried out by the use of tables and graphs.
Flow Sheets
The OCIS allows physicians to request patient, disease, and research protocoloriented flow sheets containing any data items stored in the system in one of the two general flow sheet formats. The horizontal flow displays data with the dates in columns. It is the most common format used and is illustrated in Figure 2 . A vertical flow is most commonly used to show changes in a few data elements over longer periods of time. A sample is illustrated in Figure 3 . Figure 2 shows seven patient encounters in chronologic sequence. Under each date, the following information is shown: The patient-related clinical findings are provided first. This section shows temperature, weight, blood pressure, and other "vital signs." This is followed by a graded quantification of symptoms and a direct measurement of the cancer shown in centimeters taken in cross-diameter measurements. Hematology values, blood chemistries, and treatments are then tabulated. By reading across columns, one can see trends in blood counts, the size of measured tumor masses, and the exact doses of medications that were administered. All clinical data can be displayed in this format. To shorten the display, physicians can request flow sheets of portions of this table, which may be presented in different sequences useful for specific medical needs. Data in the flow format can be reviewed or ordered on line by a physician, nurse, or other medical personnel. It also can be provided periodically by the system as a "standing order. ' ' Figure 3 shows a vertical flow, which allows for more than 7 days of data to be displayed for up to seven data items. This figure shows serum and urine protein data for a patient with multiple myeloma. A variety of protein types are listed at the top, including serum immunoglobulins and 24-hour urine measurements of total protein and of globulin light chain indicated as BJ protein. Changes in these measurements in relationship to time can be seen by reading down columns, thereby providing an overview of the patient's disease as reflected in changes in the abnormal serum immunoglobulins. Although these tables are extremely useful for evaluation of patient course, this format has limitations in that the magnitude of the change is not immediately obvious on a rapid scan of the data and, more important, the rate of change is not apparent. The table compresses time intervals between samples, and the user must take careful note of the date shown along the left column to be able to recognize temporal changes in the data. The OCIS has overcome this limitation by graphing data.
Plots
The use of graphs of related data items is being used more and more commonly to interpret absolute values, change in data, and the rate of change. When viewed graphically, many medical problems are seen to be dynamic processes, and current events are more easily explained in relationship to a plot of those that have preceded it. time indicates in a clear fashion the effect of medical treatment. This becomes a powerful tool for planning patient care and for teaching about disease and its treatment. In Figure 4 , one can see that the white blood cell count is normal at the time that a dose of cyclophosphamide is given. Nine days later the white blood cell count has decreased to a level below 1,000 per cu mm, a level at which the risk of infection is greatly increased. The plot shows that the white blood cell count remained below the 1,000 level for 7 days and then returned toward normal, passing again through 1,000 14 days after cyclophosphamide treatment. This graph also shows the temperature plotted in the upper curve. The Oncology Center infectious disease support protocol requires that patients be begun on antibiotics if they become febrile while in aplasia. Fever is defined as a temperature of 38.3 ° or higher. This graphic indicates that the temperature did cross that threshold on day 10 and that the patient was started on antibiotic support drugs of carbenieillin and trimethoprimsulfamethoxazole on that date. A rapid response to the antibiotics is indicated by the temperature fall toward normal. The patient was continued on antibiotics until the white blood cell count rose above 1,000, at which time antibiotics were discontinued, and when no recurrence of the fever was noted the patient was discharged home. A second cycle of treatment is also shown beginning 1 week later.
This figure illustrates how clinical support plans can be defined and specific threshold parameters indicated for computer monitoring. Patients whose measurements reach those levels can have prompt intervention. Using defined clinical care modules, a series of optimal care plans are being devised to help support blood product administration, the administration of intravenous fluids, and the management of electrolites, nutritional support, and other medical problems.
Daily Care Plans
Research protocol management and optimal patient care require a reminder system to assure complete and timely collection of all data needed to evaluate a treatment. The problems of failure to collect the appropriate data on the correct day, and in some instances at the correct hour, are critical issues in cancer management. Too often clinical decisions are made using incomplete data, or valuable information for research is lost due to a failure to collect important data at the correct time as designated by a study protocol.
The daily care plan is a prospective synthesis of several treatment plans. Herel a series of diagnostic and treatment protocols can be integrated to provide a statement of what is to be done for that patient on any given day. Tests that are to be done, care that is to be administered, and who is to carry out these procedures can be shown. The plans include tasks performed by nurse, physician, physician assistant, and laboratory technician. In addition, the activities of the day can be organized so that the physician responsible for the patient's care can review all activities planned for the patient in advance and can exercise greater control over the patient's overall treatment plan. Figure 5 shows the daily care plan for a patient with acute leukemia treated with Cytosine Arabinoside and Daunorubricin. Treatment day, tests, decision points, and medication to be administered can all be synthesized on a single page. In many instances, patients may also be participating in additional research protocols studying antibiotics, 
THE OCIS AND CENTER ADMINISTRATION
This section describes how the OCIS has supported basic administrative functions in the JHOC. In addition, it will describe the unique OCIS approach to basic reporting responsibilities, which has led to broader and more creative administrative uses. The development of OCIS applications that support administrative needs were not developed as ends unto themselves; rather, they are by-products of a data system oriented toward individual patients and the resources that are used to support optimal patient care.
The OCIS is responsible for managing a variety of routine reporting, recording, and analysis functions for the center administration. The central business office and the inpatient, outpatient, and nursing administration units have benefited from the OCIS because it has provided (1) centralized mechanism for recording and reporting patient activity; (2) uniformity of data collection procedures, report format, and content; (3) improved accuracy and timeliness; and (4) formating flexibility. Four applications are briefly described below.
The Census
The term census is given a broader meaning than is normally used in typical hospital systems. It is a data base that contains a record for every patient seen in the center since the facility opened in the fall of 1976. The OCIS produces many census reports in a number of formats. As shown by measures of requests for information, generation of different listings using the census file is the most heavily utilized OCIS administrative service.
Because the OCIS has been implemented using a DBMS, the census file is integrated with the total data base. Census reports typically use the basic demographic information plus the history of inpatient admissions, OPD visits, outside consultations, and protocol activities. The census is available on line, and routine reports are prepared for (a) today's inpatient census; (b) a census covering all patients admitted, seen as an outpatient, or with a major protocol activity within a specified time period; (c) a census sorted by protocol or diagnosis; (d) a census of scheduled admissions; and (e) unit-specific census reports that include patient status and recent test results.
One application of a census that is not common in most other hospital systems is the admitting census ( Figure 6 ). This is produced each day, is available in hard copy or on line, and is used to project bed availability. For each unit the current census is printed with an estimated remaining length of stay for each patient. This length of stay is updated daily by the clinical data coordinators; values of 7 or fewer days before discharge tend to be very accurate. Figure 6 . Admitting census.
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Combined with the present census is a report of the scheduled admissions. Two types of admissions are identified: those for patients involved in a therapeutic cycle that requires hospitalization on a specific date, and those where admission date is more flexible. These two pieces of information are combined and a projected census is printed. The report is used by the admitting officer when admission decisions are made. It is common practice to treat patients in an ambulatory setting and admit them only for anticipated periods of asplasia. This complicates the administrative process but results in a significant savings to the patient.
Level of Care Reporting
The OCIS provides center administration with the opportunity to manage current resources and to anticipate future needs in areas that may be pivotal in assuring a sound financial posture for the center. We are using the system to understand the rapidly changing needs of nursing administration and to support decision making in determining nurse staffing levels, deployment, and utilization. Further, by use of level of care reporting, the center is developing creative alternative solutions to the increasingly more stringent fiscal documentation requirements of federal, state, and third-party payers.
The level of care is a numerical quantification of individual patient acuity, collected daily from inpatient units and entered into the OCIS data base. It is a nurse-physician developed rating system that quantifies personnel and resources required to provide individual patient support. It is reported by both patient and unit and thereby provides an index to the patient's level of acuity as well as the unit's cumulative support needs.
Administrative interest in level of care has resulted from the need to respond creatively to two complex issues that confront the center. First, level of care has been used to help determine nursing staff levels and deployment, and to analyze utilization. Second, administrators have developed an imaginative level of care-based rate scheme in response to the increasingly more austere financial environment that planners see in the future. Figure 7 displays a typical level of care summary report for a single unit. Reports are also available by patient or diagnosis, and plotted as a function of protocol or diagnosis.
The Tumor Registry
The Tumor Registry at Johns Hopkins was established in the late 1950s. Since then it has accumulated approximately 40,000 abstracted cases of all patients with cancer Figure 7 . Care summary report for a single unit.
diagnosed throughout the Johns Hopkins Hospital. The registry became part of the OCIS and was converted to an automated system in 1976. All of the approximately 12,000 cases diagnosed at Johns Hopkins since then are available upon request. The principal administrative benefits derived from the registry function have been drawn from the existing abstract format shown in Figure 1 . As a regional facility, a significant portion of center patients are referrals. Thus, the link between the center and the referring physicians is a vital one. Maintaining this large and growing network is an essential activity, which is supported in large part by the registry function. Since the abstract contains the name and mailing address of each referring physician, the task of sending routine medical notes and other information to referring physicians is facilitated.
The demographic portion of the abstract provides the capability to search the abstract file by zip code. This function allows for definition of the geographic characteristics of the center's patient population. Site visits, grant proposals, and regulatory compliance frequently require such information. Along with the detailed classifications of diagnosis, the registry can provide information that describes geographic prevalence of disease, incidence by age, etc.
Appointment Scheduling
The JHOC Outpatient Department comprises a number of semiautonomous departments that provide servives to approximately 1,500 patients annually. Medical care is delivered through specialty clinics designed to focus on the specific expertise of the medical staff, for example: leukemia, bone marrow transplantation, solid tumor, breast cancer, etc. Supporting these clinics, and located in the outpatient facility, are the oncology pharmacy, hematology laboratories, a satellite medical records unit, social workers, billing clerks, and other support personnel.
The outpatient appointments scheduling system was developed to coordinate patient visits with the specialty clinics on the day and time they are held. The appointment system supports the features that are common to most such systems. It provides for online scheduling, rescheduling, and cancelations; checks for overbooking or inappropriate times by clinic and provider; automatic generation of encounter forms; linkage with the charge capture process; and preparation of special reports for different functions.
As an administrative tool, the appointments system has the ability to produce statistical summaries for analysis of facility use. The system routinely tabulates and reports (1) total patient visits (per day, week, month, etc.), (2) new admissions, and (3) visits by specialty clinic and provider.
The system also schedules lab work, X rays, social worker encounters, pharmacy, and other ancillary services. By encompassing all of the ancillary units, the appointments scheduling system at the JHOC outpatient department coordinates the complete range of activities.
Each ancillary unit and all providers are treated independently; thus, schedules are produced for each. Each person and unit can be apprised of its work load tabulated in 15-minute intervals for up to 6 months in advance. For example, appointment schedules are produced daily for the satellite medical records unit and are delivered on the day preceding each patients visit to facilitate chart preparation. By combining all activities into a single schedule the OCIS reflects a more realistic picture of planned activity.
As patients conclude each visit to the center, they are provided with a comprehensive return appointment plan in which all scheduled services are coordinated. A step-down routine, controlled by registrars, allows realistic time intervals between planned events that constitute a patient's next visit. The registrar can space events (for example, the interval between lab work and physician encounter) in response to demand placed on the facility, or other anticipated delays.
Treating each ancillary service as part of a larger whole provides the capability to more efficiently utilize the physical facility and the resources that must be in place to support patient visits. Staff and inventory levels can be adjusted on the strength of this.
Perhaps most important of all, the appointments function minimizes patient waiting time. This is a particularly acute concern of medical providers in general, and especially so at the center. As a regional facility, the JHOC receives patients from across a wide geographic area. Consequently, a significant number of patients travel substantial distances to and from the center. Through the appointment system, all segments of a patient's visit are realistically timed, permitting adequate intervals between them. The system assures, for example, that time is available between initial blood drawing and determining counts, and between the results of blood work and the physician encounter. Computermanaged patient flow tends to reduce the situation where preliminary procedures or the results of important tests are incomplete or unavailable at the time of patient-physician encounter. Patients can reasonably expect to step through one event to another with minimal delays. This encourages patients and physicians to arrive at their scheduled time and to expect the system to utilize their time effectively.
Development of the OCIS, therefore, recognized that the information needs of an organization as complex as the JHOC could not be easily or neatly categorized. Distinctions between what is purely clinical and what is administrative are, and should be, blurred. No organization can operate without timely information. To the extent that common information can be shared, organizational effectiveness can be increased. The OCIS plays a large part in the informational needs of the center and in making it a more effective organization. It supports a great range of programs and projects, and the administrative component is actually among the least dramatic of its achievements.
THE HEMAPHERESIS TREATMENT CENTER
Some degree of bone marrow suppression is associated with most forms of cancer chemotherapy. This is manifest as leukopenia, anemia, and thrombocytopenia. The morbidity of leukopenia and resultant infections has been reduced with appropriate antibiotic therapy and anemia corrected with red blood cell transfusions. Likewise, the morbidity and mortality of thrombocytopenia has been reduced by effective platelet transfusion support. From 1950 to 1960, hemorrhage secondary to thrombocytopenia accounted for 50% of the deaths during treatment of acute leukemia. With platelet transfusion support, this has now been reduced to less than 5%.
Delivery of comprehensive platelet transfusion services is complex. Thrombocytopenia may develop rapidly and when associated with hemorrhage requires immediate transfusion. By electively transfusing patients who are anticipated to be severely thrombocytopenic, the need for emergency platelet transfusion can be reduced. Total hospital requirements for platelet concentrates vary depending on the diagnosis, treatment, and number of patients hospitalized. Over the last 5 years at this center, utilization has varied from 50 to 200 units/day.
Platelet concentrates for transfusion may be prepared from individual units of whole blood or directly from donors by plateletpheresis. During plateletpheresis, whole blood is withdrawn from a donor, anticoagulated, and separated into components by centrifugation. The platelet fraction constituting less than 5% of the volume of blood processed is retained and the other components are returned to the donor. During a 1-to 2-hour plateletpheresis one donor can give 5-10 units of platelets. Platelet concentrates prepared from whole blood may be stored 3-5 days after collection, whereas those prepared by plateletpheresis must be used within 24 hours. The long storage time of platelets prepared from whole blood makes this product superior in terms of inventory control. However, to achieve an effective dose of platelets for an adult, concentrates from 5-10 different units of whole blood must be pooled together. An equivalent number of units can be prepared from one donor by plateletpheresis. This product has the advantage of reducing the risk of posttransfusion infections such as hepatitis. In addition, only plateletpheresis products may be used when specific HLA-typed platelets are required. HLA matched platelets are required after patients become immunized to HLA mismatched platelets. Improved therapy and longer survival in many malignancies has increased the number of patients requiring HLA matched platelet support.
Multiple factors must be integrated to provide effective platelet component support. Patient census and treatment planning must be carefully monitored to anticipate needs. Daily platelet counts and clinical status of patients must be evaluated and the need for matched platelet transfusions identified. This must be coordinated with product supply and the time constraints of storage.
System Description
At this center platelet production and transfusion services have been centralized as the Hemapheresis Treatment Center (HTC) and the overall flow and organization of data integrated into the OCIS. In this section we will describe the organization and function of the platelet support program.
The task of the HTC is to assure that each day an appropriate platelet concentrate is available for each patient's clinical situation. The HTC data support system was designed to coordinate the clinical and laboratory information required to meet this need. The data flow of the HTC system is summarized in Figure 8 . Its design and operation can best be understood by following an individual platelet concentrate through the system.
A master file of all patients receiving therapy that is anticipated to result in thrombocytopenia is maintained by the HTC. Each patient's hematologic status and the outcome of prior transfusions are reviewed daily and an estimate of the transfusion requirement for the next week is updated. If a patient requires HLA matched platelets, the master donor file containing the HLA type of over 1,000 individuals is searched to identify appropriate donors. A master summary of all projections is then prepared and forwarded to the scheduling office. Individual donors are scheduled, taking into consideration availability of plateletpheresis equipment and personnel, and donor availability and preferences. When a master schedule is prepared, donor histories containing their prior donation experience are printed and forwarded to the donor room. On the day of donation each plateletpheresis product is assigned a unique sequential identifying number. This number is then used to identify all tests performed on the product. After production, the platelet content of each product is determined and an expiration date and time assigned. The product is then entered into the current inventory. Entry of pre-and postdonation donor platelet count, volume of blood processed, machine number, and operator allows calculation of the efficiency of each platelet collection and longitudinal analysis of trends in machine and operator effeciency.
The current inventory containing products, platelet content, ABO and HLA type, and outdate time is used by the transfusion coordinators in making all product assignment. In addition, the current inventory functions as a key quality control point for the system. The inventory is programmed to require definition of product data for all sequential identifying numbers. Operators are reminded if a number is undefined, thereby assuring complete data entry. Likewise, products remain in the inventory until one of three dispositions is decided: transfusion to a patient, utilization for quality control, or destruction because of outdating. Products remaining in the inventory past their outdate time indicate that clinical flows and billing are incomplete.
An individual transfusion history is maintained on each patient ( Figure 9 ). Clinical data relevant to platelet transfusion outcome is entered daily. Such data include the maximum daily patient temperature and a 0-to-4 score for infectious disease status and clinical evidence of bleeding. Patient platelet counts and platelet transfusions are entered by time and the transfusion efficiency calculated. One unit of platelets infused into a patient with a surface area of 1 square meter should produce an increase in platelet count of greater than 5,000/mm 3 1 hour after the transfusion. With normal platelet consumption, the increment should exceed 2500/mm 3 20 hours after the transfusion. Posttransfusion increments are calculated for each transfusion and outcomes that are less than expected are analyzed. Transfusion failures frequently indicate the presence of alloimmunization and the need for HLA matched transfusions. When such transfusion failures are identified, adjustments in donor selection and scheduling are made.
The HTC data system was designed primarily as a clinical system allowing physicians to evaluate the outcome of platelet transfusion support. Secondarily, it serves as an important management tool. Utilization statistics by clinical unit and protocol allow accurate projections of needs and realistic budget planning. Production statistics are then compiled to compare day-to-day operations to budget.
Evaluation
A quantitative evaluation of the impact of the HTC computer-based transfusion service on clinical care is difficult. Since April 1978 elements of the system have been sequentially introduced. Prior to this time there was no comprehensive data base of services, and consequently there is no control period to compare with current function. However, the impact of some services has been dramatic enough to indicate that clinical care has been improved. Prior to the introduction of a comprehensive system to identify transfusion failures and to deliver HLA matched platelets, management of the alloimmunized patient was difficult. Although ineffective, nonmatched platelet concentrates continued to be given to the alloimmunized patient for lack of alternate treatments. Blood loss was replaced with red cell transfusions until death or resolution of the aplasia. When HLA matched platelet support became available, such bleeding episodes could be controlled with effective platelet transfusion. The treatment history of one patient, G.B., a 36-year-old patient with acute myelocytic leukemia, is indicative of this change ( Figure  10 ). On her first admission in 1980 she was severely alloimmunized but could not be given HLA matched platelets because she had not been HLA typed prior to treatment. She developed thrombocytopenia refractory to transfusion and severe gastrointestinal bleeding requiring 81 units of blood. Her second admission was less stormy, but because of the limited availability of blood donors of the appropriate HLA type, she experienced another episode of thrombocytopenia and bleeding with use of 31 units of blood. On her last two admissions comprehensive matched platelet support was available and during these admissions her platelet count was effectively supported. No bleeding developed and her blood product utilization was normal for patients undergoing intensive induction therapy.
To determine if such improvement could be appreciated throughout the Oncology Center, platelet transfusion practices over a 3-year period were reviewed. The clinical requirement for platelet transfusion was estimated by determining the total number of days each month that patients manifested platelet counts less than 20,000/ram 3. Over the study period the total need for transfusion doubled from approximately 200 patients/ month to 400 patients/month ( Figure 11 ). This is consistent with the expanding census of the center as patient referral increased. The rate of utilization of platelets was determined by dividing actual platelet use per month by patient days of platelet counts below 20,000/ram 3. Results indicated that during the study period there was a 50% decrease in the number of units transfused per thrombocytopenic patient day. Troughout the study period it had been recommended that 5 units of platelets be transfused on every day that April 1981 At least two factors have contributed to this improvement in transfusion practices. First, the availability of HLA matched platelet transfusion support has decreased the ineffective use of mismatched transfusions. Second, with a timely and accurate data base, transfusion specialists were better able to supervise transfusion practices and to modify inappropriate transfusion practices. We feel these data indicate that the HTC and data system have had a major impact on the quality of transfusion outcome as well as having led to significant cost savings.
The integration of the HTC into a centerwide data system has not only improved the efficiency of operations but also created a comprehensive data base that has facilitated research in transfusion support. Ongoing research has identified important genetic and treatment factors that influence the development of alloimmunization to platelets, in addition to important factors useful in HLA matching of platelets.
Undoubtedly the major factor in the improvement in platelet transfusion outcome has been the introduction of new technologies. The development of HLA typing services and the introduction of plateletpheresis equipment have revolutionized our ability to deliver matched platelet transfusions. However, without a comprehensive data system these technologic advances could not be efficiently applied to patient care.
MANAGEMENT OF INFECTIOUS DISEASES IN IMMUNOCOMPROMISED PATIENTS
Host defenses to infectious agents are frequently altered in cancer patients by the nature of the underlying disease and/or the therapy employed to treat the disease. The types of infections encountered vary with the defects noted in host defenses. For example, in the granulocytopenic patient (WBC < 1000 polymorphonuclear cells/mm 3) fever alerts the physician to suspect systemic infections with bacteria or fungi. The policy of initiating broad-spectrum antibacterial antibiotics therapy in the febrile (>38.3°C) granulocytopenic patient has led to decreased morbidity and mortality from bacterial infections. This approach has allowed physicians to employ more aggressive chemotherapeutic schedules in the treatment of malignant diseases.
The wide range of pathogens responsible for infectious complications in cancer patients with differing deficiencies in host defenses requires an organized approach to the acquisition of clinical data so that optimal therapeutic schedules may be developed. The data base that is assembled may be used in several different ways to improve patient care and to support research in the epidemiology and control of these serious infections.
Patient Treatment
For the individual patient, the data system provides up-to-date results of all clinical cultures obtained. This information is available in three different forms: (1) chronologically, (2) by organisms, and (3) by body site. The chronological data are particularly useful for the day-to-day management of the individual patient. Positive as well as negative culture information is provided. All positive cultures are reported by species, and antibiotic sensitivities are provided if deemed necessary. Surveillance culture data are provided as well as information on organisms isolated from an infected site (e.g., blood). Surveillance cultures are obtained twice weekly from throat and stool in patients who are at risk for developing infections with bacteria that are resistant to the antibiotics used to treat the initial infection in drug-induced granulocytopenia. Positive surveillance cultures alert the physician to the possibility that the patient is or may be infected with a bacterial organism that is resistant to the antibiotics the patient is receiving and thus prompt a switch in the antibiotic regimen employed. Not only are these potential pathogens identified but their sensitivities to antibiotics are provided as well so that appropriate antibiotic changes may be considered.
The culture information is also available by organism. This allows physicians to analyze data to better understand the importance of a particular pathogen as an infective agent. This information is important not only for the individual patient but to studies on larger groups of patients. For example, the OCIS is equipped to provide information listing the patients who had bloodstream infections with a specific bacterial pathogen. This information allows physicians to determine the incidence of infection with a specific pathogen and has allowed us to identify Staphylococcus epidermidis as a major cause of infection in our granulocytopenic patients. Using the chronological and organism data, we can effectively monitor the epidemiology of infections on our inpatient units and determine whether there are clusters of infection requiring intervention by our hospital infection control team.
The information system has been helpful in evaluating our surveillance culture system. Using the data presented by site, we determined that surveillance cultures of stool were more helpful in predicting infection with bacteria than were respiratory or urine cultures.
Antiviral Research
The OCIS has also been utilized to define infections in specific patient populations so that new antiinfective agents may be studied. An example of this is our study evaluating the new antiviral drug acyclovir. A retrospective review of herpes simplex virus (HSV) infections in bone marrow transplant recipients was done using the data-retrieval system. The culture by organism format revealed that 43% of all marrow transplants developed HSV infections in the posttransplant period. In addition, if we evaluated infections based on pretransplant antibody titer to HSV, two groups of patients could be identified. Those who had antibody titers to HSV had a 73% incidence of infection, while those with absent antibodies had only a 14% incidence of infection. Using the culture by site format, we determined that 85% of the infections occurred in the oral cavity and that 15% occurred in the genital area. The culture by chronology data indicated that infection occurred a median of 8 days following transplantation. Therefore, we were able to identify a subpopulation of BMT recipients with a high incidence of infection (73%) that occurred at a predictable time. This population was selected to evaluate a new antiviral agent--acyclovir. Acyclovir is an analogue of deoxyguanosine, and in vitro studies suggested that it was a potential inhibitor of HSV replication. All patients who had antibody titers to HSV and received a bone marrow transplant were placed on a randomized double-blind placebo-controlled study to see if the drug was capable of preventing HSV infection. The study was designed so that patients were evaluated in groups of 20 to see if the drug was effective. After 20 patients had been entered on the study, the results were statistically significant. As expected from the retrospective data, 7 of 10 (70%) of patients who received placebo developed culture-positive infection. In contrast, 0 of 10 patients who received the drug developed infection (p ~< .003). This study was one of the first trials in humans demonstrating the potent anti-HSV effect of this novel new antiviral agent. Additional studies done in varying patient populations have confirmed that the drug is an exciting development in antiviral therapeutics.
In this short review, it is clear that an efficient, orderly information-collection system is important for the management and understanding of infectious disease complications in cancer patients. The system not only has application for individual patients but is a resource for understanding the epidemiology of infectious patterns in groups of patients. The information that is stored is being utilized as a research tool to help in the design of studies addressed to improving the treatment and prevention of infectious complications in patients receiving treatment for their malignancy.
Mathematical Models: Improved Methodology for Measuring Treatment Response
In addition to providing for collection, storage, and display of data that can be used for retrospective and prospective research projects, the completeness, timeliness, and accessibility of data in a computer-based system lends itself to new approaches in treatment planning. An example of this is a study that we have carried out on the initial rate of change of tumor size as a predictor of clinical outcome (complete or partial response) and survival.
Generally, treatment plans are prepared in clinical trials by establishing evaluation criteria and then administering two or more cycles of treatment over the next several months. At the end of that time, an assessment of response of objective parameters is carried out without much consideration of rate of change occurring between the beginning of therapy and the time of evaluation. Therefore, all patients who are recorded as having a partial remission at 2 months are considered to be similar whether they have arrived at that point promptly and then have had a plateau of response or have gradually been approaching this level of remission at a steady rate over that same 2-month period. With the multiple alternate treatment options now available for very responsive diseases such as Hodgkin's disease, malignant lymphoma, or small cell cancer of the lung, changes in treatment plans can and probably should be made as early as possible in individual patients in an effort to achieve a complete remission and improve survival.
To examine the potential for this approach, studies have been carried out in which the period of tumor response immediately following chemotherapy has been examined as a predictor of overall outcome. In small cell carcinoma of the lung, 29 patients were studied with serial measurements of their tumor mass seen on chest X ray during the first 28 days following chemotherapy. The rate of change was assessed and study groups were defined using tumor halving times. The reduction of tumor volume expressed as a proportion of pretreatment volume following therapy ranged between .02 and .65, with a mean of .26. Using this mean as a discriminant, survival analysis indicated that patients whose tumor mass was less than .26 at 28 days had a median duration of survival that was significantly longer than the median survival for patients with greater than .26.
It is now possible to integrate mathematical predictive models into the clinical data system and examine prospectively the observed response. This is especially useful for diseases where tumor regression is seen in a high percentage of patients who are initially treated and in whom the potential for cure may depend on selection of treatment based upon individual characteristics. When a treated tumor mass is shown to be following a model indicative of a poor outcome, prompt change to an alternative drug regimen or to a more intense dose and schedule of treatment is indicated.
Our current plans include the routine presentation of the trend data and evaluation of this technique in a prospective study.
S Y S T E M E V A L U A T I O N
The evaluation of a clinical information system can be measured in three ways.
Utilization. This is a quantification of how and where the system is used. Clearly, high usage indicates that the system is an integral part of the health care process. Further, high usage levels would suggest that the system is perceived to be beneficial.
Cost. This is a quantification of the cost of the system for both one-time development and operations. It includes all costs that are associated with the information system and is limited to the cost of operation within the facility.
Cost benefit. This is a quantification of the net cost impact of the system, i.e., the difference between the operating costs with the information system and the projected cost of operations if no computer system existed.
Each element will be examined separately.
Utilization Measures
The OCIS operates 7 days a week and is the primary support for clinical data displays, clinic scheduling, patient admission, tumor registry operation, the pheresis program and test ordering. Table 3 summarizes some weekly utilization statistics based upon 1981 operations reports. The activity in 1982 is essentially the same; however, newly introduced hospitalwide computer reporting of laboratory results and the implementation of the Phase II OC1S have resulted in short-term distortions.
A second indication of utilization is the catalog of newly requested applications. During the past 12 months a parallel system was established for Pediatric Oncology, all radiation therapy activity is being processed by the OCIS for both charge capture and reporting, a unit dose pharmacy system was implemented, and new protocol on study forms has been developed. There is also a list of pending applications to be initiated after the Phase II conversion is completed.
System Cost
The cost of the system is divided into one-time costs and ongoing operational costs. The one-time costs include facility preparation, computer equipment, and OCIS software development. The facility preparation cost includes both the planning and cable installation in the original building and the changes made to the original facility. The latter includes the cost of supplementary air conditioning. Total facility costs were about $100,000 to 150,000.
Computer equipment costs include two PDP-11/70 computers, four RP-06 disk units (700 M bytes of storage), terminals, and communication equipment. Total equipment costs over a 5-year period are about $600,000.
Software development costs for the OCIS include both initial system development and system maintenance. The Oncology Center's accounting does not differentiate between categories. However, given the current design together with a trained staff, the Searches, queries, 50 N/A special requests entire system could be reprogrammed in about 12 man-years of effort. Thus, we have assumed a development cost of $300,000, with all other software costs allocated to system maintenance.
The total one-time OCIS cost is about $1 million. A large part of that investment was for equipment at prices that prevailed 5 years ago. For example, the total mass storage used by the OCIS can now be replaced by a single unit at about a fourth of the initial price. With the equipment available on the market today, the same computing capability can be purchased at two-thirds the initial cost. If one were willing to assume some technical risk and use prototype data base machines, small MUMPS processors, and local area networking, then the equivalent power would be available for about onefourth the price. And if one is willing to wait 3 to 5 years, there will be no technical risk associated with such an inexpensive configuration.
Operational cost for the OCIS includes (a) computer operations with operators and data entry, (b) software maintenance including OCIS enhancement, and (c) clinical data coordinators who act as an interface between the information center and the users of the system. The Oncology Center employs a faculty of 80 and a staff of 500. The Information Center staff supports 1 faculty member and a staff of 20. Ten of the staff are clinical data coordinators who are assigned to the clinical units.
Support for the Information Center is taken from different cost centers within the Oncology Center. With the exception of'some separately funded research activities, all operating costs are derived from patient care revenues. The Information Center assessment is based on a guideline of 3% of the charges for the services supported. (The 3% figure includes a 5-year write-off of the capital investment.) Units supporting the Information Center include Medical Oncology, Pediatric Oncology, Radiation Oncology, the Pheresis Center, the Oncology Pharmacy Center, and the Administrative Offices.
Cost Benefit
The evaluation of cost benefit is a difficult task that is seldom done well and never done inexpensively. In evaluating the OCIS, it should be clear that no manual system could provide the functionality of the automated system. Thus, a cost-benefit analysis would be comparing unlike capabilities.
Second, it must be recognized that the traditional methods for cost-benefit analysis consider only those items appearing in the institution's budget. Cost savings to other segments of the economy usually are not tabulated. Yet some of the most dramatic cost savings that result from the OCIS involve cost savings to patients and third-party payers that may have a negative cost impact on the Oncology Center. The example provided previously in the preparation of platelets from pheresis is an illustration of this.
Evaluation Summary
The OCIS is used. Its primary support comes from patient care revenues. The cost of operation is about 3% of the clinical service charges. Its benefits have been demonstrated anecdotally and formally. Based upon the experience with other systems, the use of the OCIS also improves research protocol compliance. Finally, the availability of a large clinical data base provides a resource for patient care decision making, quality assurance audits, and research.
The one-time cost of the OCIS is a function of equipment cost plus the cost of initial software development. Because the OCIS has been developed with TEDIUM TM, modification and decomposition of functions has been simplified. There are many small computer systems available today that can support four to eight users, manage a data base of 30 million characters, and sell for under $20,000. Major OCIS functions will operate on such systems. As the cost of equipment continues to fall, users of systems like the OCIS will find that the major costs are those of operations.
